CDW Holding Limited
Room 6-10, 11/F, CCT Telecom Bldg.
11 Wo Shing Street, Fo Tan, Shatin
New Territories, Hong Kong
www.cdw-holding.com.hk

MEDIA RELEASE

CDW's subsidiary ABio and Neoregen sign joint R&D agreement for next-generation Lipid Nanoparticle technology

- **Joint R&D agreement enables Neoregen and ABio to deepen research into LNP technology and mRNA vaccines**
- **Create synergies between ABio and Neoregen through proprietary know-how and technology sharing**

Singapore, 20 January 2025 – SGX Mainboard listed CDW Holding Limited ("**CDW**", the "**Company**", and together with its subsidiaries, the "**Group**"), wishes to announce that its subsidiary A Biotech Co., Limited ("**ABio**"), an antibody research and drug development company, has signed a joint research and development ("R&D") agreement with Neoregen Biotech Co., Ltd. ("**Neoregen**") for next-generation Lipid Nanoparticle ("**LNP**") technology.

Background

Neoregen is a South Korean company that has its own peptide-based drug delivery technologies, cutting-edge cell penetration technology and is developing various DNA or RNA-based therapeutics. ABio's main business activities include the development of various antibodies using its proprietary antibody library and the production of recombinant antibodies.

This Agreement will enable ABio to extend its research capabilities into LNP technology through this joint R&D collaboration with Neoregen, a leader in this field. LNP technology

plays an important role in mRNA vaccines and the joint R&D effort aims to drive synergies between ABio and Neoregen through proprietary know-how and technology sharing.

LNP technology has been one of the most successful nano-delivery vehicles that enable efficient delivery of cytotoxic chemotherapy agents, antibody, and nucleic acid therapeutics, including messenger RNA ("**mRNA**") vaccines. During the COVID-19 pandemic, Pfizer/BioNTech and Moderna successfully developed LNP-based COVID-19 mRNA vaccines, and based on this success, worldwide development of LNP-based mRNA therapeutics is gaining momentum due to their potential in the development of vaccines and therapeutics for various genetic diseases and cancers. Furthermore, bioimaging techniques can also be utilised to evaluate pharmacokinetics and pharmacodynamics ("**PK/PD**") effects, which helps the discovery of target drugs and accelerates the development of LNP-based mRNA therapies.



Figure 1 – Lipid Nanoparticle Composition (Source: A Biotech Website)

mRNA and LNP Technologies

mRNA technology is used in the development of vaccines against coronavirus strains, whereby LNPs function as carriers that wrap mRNA and deliver it efficiently to cells. This technology is not limited to mRNA vaccines, and research is also being carried out in fields such as cancer treatment and gene therapy, contributing to further innovation in medical technology.

An issue with conventional LNP technology is that LNP containing polyethylene glycol ("**PEG**") which can cause hypersensitivity reactions and allergic reactions in the human body. In addition, LNP technology used for mRNA vaccines requires very strict temperature control, and there are concerns that LNP stability may be compromised by temperature fluctuations during transport.

Therefore, while LNP technology is leading the way in innovation in the pharmaceutical and vaccine fields, more research and development is required to address issues related to safety and stability. For this reason, through this joint research and development effort with Neoregen, the parties will be studying if CDW's LANFA technology ("**LANFA")** can be applied to LNP, and in doing so, develop an innovative LNP technology that can resolve these issues. LANFA is a water-solubilised chemical compound which can improve hydrophilicity and water solubility of various substances, including LNP.

Mr. Kato Tomonori, Chairman and Chief Executive Officer of the Group, said: *"We are pleased to embark on a joint research and development venture with Neoregen Biotech. This partnership allows us to tap on Neoregen Biotech's cutting-edge cell penetration LNP technology and with the introduction of CDW's LANFA innovations, help to advance research and development in this field and potentially develop a breakthrough LNP product in this expanding market."*

The Group will make further announcements on SGXNet as and when there are material developments on this research collaboration.

- End -

About CDW Holding Limited (www.cdw-holding.com.hk)

CDW Holding Limited (the "Company" and together with its subsidiaries, the "Group") is a Japanese-managed precision components specialist serving the global market focusing on the production and supply of niche precision components for digital instrument panels in the automobile industry, notebook computers, consumer and information technology equipment, office equipment and electrical appliances, and an original equipment manufacturer. The Group is headquartered in Hong Kong and has operations in Japan, China, South Korea, Thailand and the Philippines. The Company has been identifying new businesses to invest in with the potential for growth and entered as part of its diversification strategy and has made forays into the Life Sciences sector since 2016. The Company's aim for its Life Sciences business is to identify research-driven yet commercialisable projects that can have a positive impact on the quality of human life.

About Neoregen Biotech Limited (http://neoregenbio.com/default/)

Neoregen Biotech Limited is a biotechnology company focused on medicine development & healthcare products using Macromolecule-delivery Platform Technology. Its vision is to develop the world's most efficient cell and skin penetration technology through continuous research, and is currently conducting research in the fields of drug delivery and microbiome probiotics technologies. It has four main segments: Neoregen Biotech which is focused on R&D; Medicine business; Cosmetics business; and Healthcare business which sells health foods.

Issued on behalf of	:	**CDW Holding Limited**
By	:	The Cogent Group
Contact	:	Derek Chng / Gerald Woon
Office	:	(65) 6704 9288
Email / DID / Mobile	:	derekchng@cogentcomms.com / (65) 6704 9285 / (65) 9638 8635 woon@cogentcomms.com / (65) 6704 9268 / (65) 9694 8364